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The apoptotic members CD95, BclxL, and Bcl-2
cooperate to promote cell migration by inducing Ca2+
flux from the endoplasmic reticulum to mitochondria
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Metalloprotease-processed CD95L (cl-CD95L) is a soluble cytokine that implements a PI3K/Ca2+ signaling pathway in triple-
negative breast cancer (TNBC) cells. Accordingly, high levels of cl-CD95L in TNBC women correlate with poor prognosis, and
administration of this ligand in an orthotopic xenograft mouse model accelerates the metastatic dissemination of TNBC cells. The
molecular mechanism underlying CD95-mediated cell migration remains unknown. Here, we present genetic and pharmacologic
evidence that the anti-apoptotic molecules BclxL and Bcl-2 and the pro-apoptotic factors BAD and BID cooperate to promote
migration of TNBC cells stimulated with cl-CD95L. BclxL was distributed in both endoplasmic reticulum (ER) and mitochondrion
membranes. The mitochondrion-localized isoform promoted cell migration by interacting with voltage-dependent anion channel 1
to orchestrate Ca2+ transfer from the ER to mitochondria in a BH3-dependent manner. Mitochondrial Ca2+ uniporter contributed to
this flux, which favored ATP production and cell migration. In conclusion, this study reveals a novel molecular mechanism
controlled by BclxL to promote cancer cell migration and supports the use of BH3 mimetics as therapeutic options not only to kill
tumor cells but also to prevent metastatic dissemination in TNBCs.
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Apoptosis occurs through extrinsic and intrinsic signaling
pathways. Whereas death receptors trigger the extrinsic
apoptotic signal, mitochondria and their regulation by the
Bcl-2 family implement the intrinsic pathway. Members of
the Bcl-2 family (which share at least one of the four domains
of Bcl-2 homology) are key regulators of the balance between
cell life and death. They control mitochondrial membrane
permeabilization allowing the liberation into the cytoplasm of
apoptogenic factors including cytochrome c, which is respon-
sible for the cascade of caspase activation. The functional
activity of pro-survival members of the family (Bcl-2, BclxL,
Bcl-w, Mcl-1, and A1) is to sequester the pro-apoptotic
members BAX and BAK, which are the executioner molecules
of mitochondrial membrane permeabilization. BH3-only pro-
teins such as BAD release BAX/BAK from their sequestration
by Bcl-2/BclxL, and thereby implement the cell death
program.1 Bcl-2 family proteins also have cellular functions
beyond regulation of apoptosis. For instance, Bcl-2 and BclxL
proteins regulate Ca2+ release from the endoplasmic reticulum
(ER) by interacting with IP3R (for review see Monaco et al.2).
Moreover, independent of its anti-apoptotic function, BclxL can
exert a pro-metastatic role in breast and pancreatic cancer
cells through a molecular mechanism that remains to be
defined.3–5
CD95 (APO1/Fas) is a death receptor that has a pivotal role
in immune homeostasis6–8 and the elimination of infected and
transformed cells in mice and humans (for review see Strasser
et al.9). Its cognate ligand, CD95L (FasL), belongs to the tumor
necrosis factor family. Full-length transmembrane CD95L can
be cleaved by metalloproteases,10 releasing a soluble ligand
whose pathophysiological functions have been investigated
only recently. A growing body of evidence indicates that this
soluble ligand aggravates inflammation in chronic inflamma-
tory disorders11,12 and promotes oncogenesis13–16 by indu-
cing non-apoptotic signaling pathways such as NF-κB11 and
PI3K.12
Breast cancer represents a heterogeneous pathology in
terms of molecular profiles and clinical outcomes. Triple-
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negative breast cancers (TNBCs) are defined by a lack of
expression of estrogen, progesterone, and HER2 receptors.
Because of the absence of identified targets, treatment
guidelines for patients with TNBC include only conventional
chemotherapy, and thus prognosis remains significantly worse
for these women than for other breast tumor patients
benefiting from tailored therapies.17,18 Accordingly, the devel-
opment of new and targeted therapeutic strategies is required
to improve the treatment efficiency of TNBC patients.
We recently observed that among TNBC patients, high
amounts of serum CD95L are correlated with poor prognosis
and premature metastasis.15 Of interest, soluble metallo-
protease-cleaved CD95L (cl-CD95L) induces non-apoptotic
signaling pathways that promote metastatic dissemination of
TNBCs.15 CD95L can also promote migration of colorectal
cancer cells13 and glioblastoma cells.14 Nonetheless, the
molecular mechanisms by which this receptor promotes
oncogenesis remain to be identified.
Evasion from the apoptotic cell death program is a hallmark
of cancer cells and is also an important mechanism to explain
therapeutic failure.19 To achieve this, cancer cells exhibit
deregulation of many apoptotic factors. Of interest, the
molecular mechanisms by which these molecules prevent
cell death have been extensively studied, regardless of their
non-apoptotic functions that may also help to accelerate
carcinogenesis. Herein, we demonstrate that the anti-
apoptotic factors Bcl-2 and BclxL collaborate to induce
CD95-mediated mitochondrial Ca2+ upload, increasing ATP
production and thereby promoting cell migration in TNBC.
Results
BclxL and Bcl-2 are instrumental in the CD95-induced
cell migration. Because BclxL and Bcl-2 are instrumental in
controlling CD95-mediated apoptotic signaling, we wondered
whether these molecules also modulated CD95-mediated
non-apoptotic signaling pathways. To address this question,
we examined the effect of ABT-737 in TNBC cells exposed to
cl-CD95L. The BH3 mimetic ABT-737 exhibits high-affinity
binding to the hydrophobic BH3-binding groove of BclxL and
Bcl-2, whereas it has a low affinity for Mcl-1.20 Two TNBC cell
lines were selected according to their resistance (BT549) or
sensitivity (MDA-MB-231) to the ABT-737-mediated cell death
pathway (Supplementary Figure S1A). Using the Boyden
chamber assay, we observed that a non-toxic dose of
ABT-737 abolished the migration of these TNBC cells
stimulated with cl-CD95L (Figure 1a). Of interest, although
ABT-737 treatment did not alter CD95-mediated Akt phos-
phorylation at serine 473 or threonine 308, two hallmarks of
PI3K activation (Figure 1b), it abrogated the Ca2+ response
(Figure 1c). To further investigate the role of BclxL and Bcl-2
in CD95-mediated cell migration, we next silenced Bcl-2
and BclxL in TNBC cells using shRNAs. To rule out
misinterpretations due to off-target effects, we evaluated the
molecular and biological effects of three different shRNAs
targeting distinct sequences of the Bcl-2 and BclxL genes.
Downregulation of Bclx in MDA-MB-231 (Figure 1d) and
BT549 (Supplementary Figure S1B) cells did not affect
Bcl-2 expression but inhibited cell migration when these
TNBC cells were exposed to cl-CD95L (Figure 1e and
Supplementary Figure S1C). Similarly, a reduction in Bcl-2
expression did not alter the BclxL expression level (Figure 1f
and Supplementary Figure S1D) but inhibited CD95-induced
cell motility (Figure 1g and Supplementary Figure S1E). In
agreement with the BH3 mimetic data, downregulation of
BclxL and Bcl-2 in TNBC cells did not inhibit the CD95-
mediated PI3K signaling pathway and even enhanced it
(Supplementary Figure S1F), suggesting that BclxL and Bcl-2
exert a BH3-independent negative regulatory function in the
CD95-mediated PI3K response. Because downregulation of
Bcl-2 and BclxL expression abrogated the CD95-mediated
Ca2+ response (Figure 1h), these findings suggest that Bcl-2
and BclxL promote cell migration by modulating this Ca2+
response.
BclxL localization in mitochondrial membranes triggers
CD95-mediated cell migration. Bcl-2 and BclxL prevent the
release of cytochrome c in response to many apoptotic
stimuli.21–23 However, Bcl-2 and BclxL also associate with
other cytoplasmic membranes, notably those of the ER,24
raising the possibility that they exert different functions
according to their cellular distribution. It is noteworthy that
loss of BclxL or its reconstitution in Bclx-knockout (KO) MEFs
did not affect the expression level of CD95 (Figure 2a). BclxL
was targeted to the outer mitochondrial membrane by
replacing its membrane anchor with the mitochondrial
insertion sequence of the listerial protein ActA (BclxL-MT)
and to the ER membrane with the ER-specific sequence of
cytochrome b5 (CytB5; BclxL-ER).25 To validate the cellular
localization of these constructs, we fused each membrane
sequence to GFP (Supplementary Figure S2A) and analyzed
the distribution of GFP compared with that of ER and
mitochondrion trackers using confocal microscopy
(Supplementary Figure S2B). GFP-ActA co-localized with
the mitochondrion tracker but not with the ER tracker,
whereas the opposite was observed with the GFP-fused
CytB5 sequence (Supplementary Figure S2B), confirming
that these sequences selectively distributed BclxL to the
expected organelles.
The trivial cytosolic calcium response observed in
MEFBclxL− /− stimulated with cl-CD95L was increased in cells
reconstituted with BclxL-WT (Figure 2b). BclxL-ER evoked a
CD95-mediated cytosolic Ca2+ response similar to that in
MEFs reconstituted with BclxL-WT (Figure 2b). By contrast,
BclxL-MT failed to restore the cytosolic Ca2+ response in these
cells (Figure 2b). Importantly, although MEFBclxL− /− did not
migrate in the presence of cl-CD95L (Figure 2c), reconstitution
of these cells with BclxL-WT restored CD95-mediated cell
motility (Figure 2c). Unexpectedly, although BclxL-ER induced
a cytosolic Ca2+ response similar to that provoked by
BclxL-WT, it failed to trigger cell migration in the presence of
cl-CD95L (Figure 2c). By contrast, BclxL-MT did not restore
the CD95-mediated cytosolic Ca2+ response, but induced cell
migration in a manner similar to BclxL-WT-expressing MEFs
(Figure 2c). These latter results encouraged us to re-evaluate
the role of Ca2+ in CD95-mediated migration of MEFs. The
Ca2+ chelator BAPTA-AM completely inhibited motility of
MEFs stimulated with cl-CD95L (Figure 2d), confirming that
Ca2+ was instrumental in this cellular process.
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Figure 1 CD95 induces a BH3-dependent calcium signal that promotes TNBC cell motility. (a) MDA-MB-231 and BT549 cells were pre-incubated for 1 h in the presence of
0.1 and 10 μM ABT-737, respectively, and then treated or untreated with cl-CD95L (100 ng/ml) for 24 h. Cell migration was evaluated by the Boyden chamber assay. Migrating
cells were fixed and stained with Giemsa. For each experiment, five images of random fields were acquired. To quantify cell migration, migrating cells were lysed and absorbance
was measured at a wavelength of 560 nm. Values represent the mean± standard deviation of three independently performed experiments (***Po0.001; two-way Mann-
Whitney). Bars= 50 μm. (b) MDA-MB-231 and BT549 cells were pre-incubated for 1 h with or without non-toxic doses of ABT-737 (0.1 and 10 μM, respectively) and then treated
or untreated with cl-CD95L (100 ng/ml) for the indicated amount of time. Cells were lysed and immunoblotting was performed as indicated. Akt was used as a loading control. (c)
MDA-MB-231 and BT549 cells were pre-incubated for 1 h in the presence or absence of ABT-737 (0.1 μM). Cells were loaded with the Ca2+ probe FuraPE3 and then stimulated
with cl-CD95L (100 ng/ml). The cytosolic calcium concentration was monitored via the ratio F/F0 (relative Ca
2+
[CYT]). Data represent the mean± s.e. of the mean of F/F0 (n450
cells, at least three independent experiments). (d) MDA-MB-231 cells were infected with lentiviruses encoding shRNAs targeting different regions of Bclx mRNA. After puromycin
selection, cells were lysed and the amounts of BclxL and Bcl-2 were evaluated by immunoblotting. β-Actin served as a loading control. (e) Migration of cells depicted in (d) was
assessed using the Boyden chamber assay in the presence or absence of cl-CD95L (100 ng/ml) for 24 h. Migrating cells were fixed, stained (Giemsa), and lysed. Absorbance of
migrating cells was measured at a wavelength of 560 nm. Values represent the mean± standard deviation of three independently performed experiments (**Po0.01, *Po0.05;
two-way Mann-Whitney). (f) MDA-MB-231 cells were transduced with lentiviruses encoding shRNAs targeting different regions of Bcl-2. After puromycin selection, cells were
lysed and the expression levels of Bcl-2 and BclxL were evaluated by immunoblotting. β-Actin served as a loading control. (g) Migration of cells depicted in (f) was evaluated by
the Boyden chamber assay in the presence or absence of cl-CD95L (100 ng/ml) for 24 h. Migrating cells were fixed, stained (Giemsa), and lysed. Absorbance of migrating cells
was measured at a wavelength of 560 nm. Values represent the mean± s.e. of the mean of three independently performed experiments (**Po0.01; two-way Mann-Whitney). (h)
The calcium response was assessed in MDA-MB-231 cells infected with lentiviruses encoding various shRNAs targeting BclxL (left panel) or Bcl-2 (right panel). Cells were loaded
with the Ca2+ probe Fluo2 and then stimulated with cl-CD95L (100 ng/ml). The cytosolic calcium concentration was monitored via the ratio F/F0 (relative Ca
2+
[CYT]). Data represent
the mean± s.e. of the mean of F/F0 measured in GFP-positive cells (n450 cells, at least three independent experiments)
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Figure 2 BclxL-MT is instrumental in cell migration. (a) Bclx-KO MEFs and their counterparts reconstituted with BclxL-ER, BclxL-MT, or BclxL-WT were lysed, and the
expression levels of the indicated proteins were assessed by immunoblotting. Numbers indicate different clones. (b) The indicated MEFs were loaded with the Ca2+ probe
FuraPE3 and then stimulated with cl-CD95L (100 ng/ml). The cytosolic calcium concentration was monitored via the ratio F/F0 (relative Ca
2+
[CYT]). Data represent the mean± s.e.
of the mean of F/F0 in GFP-positive cells (n450 cells, at least three independent experiments). (c) Migration of the indicated MEFs treated with or without cl-CD95L (100 ng/ml)
was evaluated using the Boyden chamber assay. After 24 h, migrating cells were fixed, stained with Giemsa, and lysed. Absorbance was measured at a wavelength of 560 nm.
Values represent the mean± s.e. of the mean of three independently performed experiments (**Po0.01, *Po0.05; two-way Mann-Whitney). (d) Parental MEFs were pre-
incubated for 1 h in the presence or absence of a non-toxic dose of BAPTA-AM (5 μM) and then stimulated with or without cl-CD95L (100 ng/ml) for 24 h. Cell migration was
analyzed using the Boyden chamber assay. Migrating cells were stained with Giemsa. Data are representative of three independently performed experiments. (e) MEFBclxL-MT
were loaded with the Ca2+ probe FuraPE3 and pre-incubated for 1 h in the presence or absence of a non-toxic dose of ABT-199 (1 μM). Cells were then stimulated with cl-CD95L
(100 ng/ml) and the cytosolic calcium concentration was monitored via the ratio F/F0 (relative Ca
2+
[CYT]). Data represent the mean± standard error of F/F0 (n450 cells, at least
three independent experiments). (f) MEFBclxL-WT and MEFBclxL-MT were pre-treated for 1 h with or without (control) a non-toxic dose of ABT-199 (1 μM) and then stimulated
with cl-CD95L (100 ng/ml) for 24 h. Cell migration was assessed by the Boyden chamber assay. Migrating cells were fixed with methanol and stained with Giemsa. Absorbance of
migrating cells was measured at a wavelength of 560 nm. Values represent the mean± standard deviation of three independently performed experiments (**Po0.01; two-way
Mann-Whitney)
BclxL orchestrates CD95-mediated cell migration
A Fouqué et al
1706
Cell Death and Differentiation
ABT-199 is a BH3 mimetic that selectively targets Bcl-2.26
ABT-199 treatment abrogated the residual intracellular Ca2+
response observed in BclxL-MT-expressing MEFs stimulated
with cl-CD95L (Figure 2e) and prevented migration of both
BclxL-WT- and BclxL-MT-expressing MEFs (Figure 2f), indi-
cating that Bcl-2 and mitochondrial BclxL cooperate to induce
CD95-mediated cell motility. Because BclxL localization to
mitochondria is mandatory to trigger CD95-mediated cell
migration and mitochondria have a calcium-buffering ability,27
wewondered whether BclxL orchestrated CD95-mediated cell
migration by promoting mitochondrial Ca2+ uptake. The Ca2+
concentration in the mitochondrial matrix was assessed
using confocal microscopy and the mitochondrion-restricted
Ca2+ probe Rhod2 (Figure 3a). Whereas the Ca2+ concentra-
tion in mitochondria of MEFBclxL− /− did not change in the
presence of cl-CD95L, rapid and transient Ca2+ accumulation
was observed in mitochondria of BclxL-WT-reconstituted
cells (Figure 3b). Although BclxL-ER restored the
CD95-mediated cytosolic Ca2+ response (Figure 2b), it failed
to trigger mitochondrial Ca2+ uptake (Figure 3c). Importantly,
reconstitution of MEFBclxL− /− with BclxL-MT restored
CD95-mediatedmitochondrial Ca2+ loading (Figure 3d), which
was abolished by ABT-199 (Figure 3e). These findings clearly
indicated that mitochondrial distribution of BclxL is mandatory
for CD95-mediated cell migration and Bcl-2 and BclxL
cooperate to elicit mitochondrial Ca2+ uptake in cells exposed
to cl-CD95L.
BID and BAD participate in CD95-mediated mitochondrial
Ca2+ influx. BAD is a BH3-only protein that forms a
heterodimer with BclxL to displace its interaction with BAX
and induces the mitochondrion-dependent apoptotic
response.28 BAD also contributes to glucose-driven mito-
chondrial respiration by modulating glucokinase activity.29
Because BclxL and Bcl-2 prevented Akt activation in cells
exposed to cl-CD95L (Supplementary Figure S1F) and Akt
phosphorylates BAD to sequester it in the cytosol and block
its redistribution to mitochondria,30,31 we next examined
whether BAD contributed to CD95-driven cell migration.
Knockout of BAD (Supplementary Figure S3A) enhanced
CD95-mediated Akt activation (Supplementary Figure S3B),
suggesting that BclxL, Bcl-2, and BAD exert a negative
regulatory activity on Akt phosphorylation. More importantly,
BAD-KO cells stimulated with cl-CD95L did not exhibit
mitochondrial Ca2+ uptake (Supplementary Figure S3C). In
cells stimulated with cl-CD95L, BclxL interacted with BAD
(Supplementary Figure S3D) and this association was
inhibited using the BH3 mimetic ABT-737 (Supplementary
Figure S3D). In addition, BAD-KO MEFs failed to migrate in
the presence of cl-CD95L (Supplementary Figure S3E),
showing that CD95 recruits part of the classical apoptotic
Figure 2 Continued
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Figure 3 BclxL-MT orchestrates CD95-mediated calcium influx in the mitochondrial matrix. Bclx-deficient MEFs (a) reconstituted with BclxL-WT (b), BclxL-ER (c), or
BclxL-MT (d) were loaded with the mitochondrial Ca2+ probe (Rhod2, red) and cell-permeable Mitotracker (green) to label mitochondria. Left panels: confocal images of cells
stimulated with cl-CD95L (100 ng/ml) for the indicated amount of time. Right panels: a region of interest was drawn in the Mitotracker-positive region (mitochondria) and
fluorescence of the Ca2+ probe Rhod2 was monitored in this region. Graphs depict the overlay of the mitochondrial calcium response of 10 representative cells exposed to
cl-CD95L. (e) The same experimental protocol was used as in (d), except that cells were pre-incubated for 1 h with a non-toxic dose of ABT-199 (1 μM). Images show t0, t0+35 s,
t0+85 s, and t0+290 s of cells stimulated with cl-CD95L (100 ng/ml)
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machinery in the presence of cl-CD95L to trigger a non-
apoptotic signaling pathway that promotes cell migration. BID
is another BH3-only protein involved in CD95-mediated cell
death.32,33 Indeed, CD95 activation leads to BID truncation
(tBID) through a caspase-8-driven process and tBID is pivotal
to induce mitochondrial outer membrane permeabilization
and cell death.32 In agreement with the role of BID in the
CD95-mediated apoptotic signal, BID-KO MEF cells did not
die in the presence of a cytotoxic CD95L designated Ig-
CD95L34 (Supplementary Figure S3F). Cells lacking BID
triggered a cytosolic Ca2+ response similar to that observed
in parental MEF cells when exposed to cl-CD95L
(Supplementary Figure S3G) indicating that BID is not
involved in Ca2+ release from the ER to the cytosol in cells
exposed to cl-CD95L. By contrast, the mitochondrial Ca2+
uptake observed in parental MEF cells was abrogated in BID-
KO MEF (Supplementary Figure S3H), which also failed to
migrate in presence of cl-CD95L (Supplementary Figure S3I).
Finally, although stimulation of MEF or BT549 cells with
Ig-CD95L induced BID cleavage (Supplementary Figures
S3J and S3K), BID was not processed in cells exposed to
cl-CD95L (Supplementary Figures S3J and S3K), indicating
that unlike the apoptotic signal, BID cleavage is not a pre-
requisite to trigger CD95-mediated cell migration.
BAX and BAK are two pro-apoptotic Bcl-2 members
orchestrating mitochondrial outer membrane permeabilization
and thereby implementing the apoptotic signal. Although
these molecules contributed to the CD95-mediated apoptotic
signal (Supplementary Figure S3F), the loss of BAX and BAK
did not impair the CD95-mediated cytosolic response
(Supplementary Figure S3L) and even seemed to
enhance this signal (Supplementary Figure S3L). Also, the
CD95-mediated mitochondrial Ca2+ upload in MEF cells
lacking BAX and BAK remained unaffected (Supplementary
Figure S3M). Finally, BAX/BAK double KO MEF cells as well
as parental MEF cells migrated when exposed to cl-CD95L
(Supplementary Figure S3I) indicating that BAX and BAK
were not involved in the CD95-mediated non-apoptotic
signaling pathway. Overall, these findings highlighted that
unlike BAX and BAK, BAD and BID contributed to the
CD95-mediated non-apoptotic signaling pathway by promot-
ing the Ca2+ flux into mitochondria.
Downregulation of BclxL in TNBC cells inhibits CD95-
mediated mitochondrial Ca2+ uptake. To address whether
similarly to MEFs, BclxL orchestrated CD95-mediated migra-
tion in TNBC cells, we silenced endogenous BclxL in a
TNBC cell line (BT549ShBclx) using shRNAs targeting its
3′ untranslated region and reconstituted cells with BclxL-WT,
BclxL-MT, or BclxL-ER constructs devoid of the 3′ untrans-
lated region (Figure 4a). Reconstitution of BT549ShBclx with
BclxL-WT or BclxL-ER restored the CD95-mediated cytosolic
Ca2+ response (Figure 4b), while BclxL-MT failed to imple-
ment this signal (Figure 4b). Silencing of BclxL expression in
BT549 cells inhibited CD95-mediated cell migration in
comparison with parental TNBC cells (Figure 4c). On the
other hand, BT549ShBclx reconstituted with BclxL-WT or
BclxL-MT migrated when stimulated with cl-CD95L,
whereas BclxL-ER failed to restore migration of BT549ShBclx
(Figure 4c). In agreement with the MEF data, BclxL-WT and
BclxL-MT led to mitochondrial Ca2+ loading in TNBC cells
exposed to cl-CD95L (Supplementary Figure S4A),
whereas BclxL-ER did not (Supplementary Figure S4A),
confirming that BclxL residing in the outer membrane of
mitochondria was mandatory to trigger Ca2+ loading of the
organelle. Importantly, ABT-199 treatment abrogated
the CD95-mediated residual cytosolic Ca2+ response
(Figure 4d), ion accumulation in the mitochondrial matrix
(Supplementary Figure S4B), and migration (Figure 4e) in
BclxL-MT-expressing BT549ShBclx exposed to cl-CD95L.
These results clearly demonstrated that Bcl-2 and BclxL
cooperate to induce mitochondrial Ca2+ loading and migra-
tion of TNBC cells exposed to cl-CD95L.
BclxL interacts with voltage-dependent anion channel
(VDAC) 1 and modulates mitochondrial Ca2+ uniporter
(MCU) to promote cell migration. Recent data showed that
BclxL interacts with isoforms 1 and 3 of VDAC at the outer
mitochondrial membrane to activate mitochondrial Ca2+
uptake and modulate cell death.35,36 BclxL immunoprecipita-
tion revealed that VDAC3 was not present in the immune
complex formed in cells stimulated with cl-CD95L (data not
shown). On the other hand, although no association between
BclxL and VDAC1 was detected in BclxL-ER-expressing
MEFs (Figure 5a), BclxL interacted with VDAC1 in BclxL-MT-
expressing MEFs stimulated with cl-CD95L (Figure 5a).
Using co-immunoprecipitation (Figure 5b) and proximity
ligation assay (Supplementary Figure S5A), we observed
that a residual level of BclxL (wild type and MT) interacted
with VDAC1 in unstimulated BT549ShBclx reconstituted with
BclxL-WT or BclxL-MT cells (Supplementary Figure S5A),
whereas no such interactions were detected in BT549ShBclx
reconstituted with an empty vector or with BclxL-ER (Supple-
mentary Figure S5A). Furthermore, the number of VDAC1/
BclxL interactions significantly increased in BclxL-WT
(Supplementary Figure S5A)- and BclxL-MT-expressing
BT549ShBclx cells exposed to cl-CD95L (Figure 5b and
Supplementary Figure S5A), whereas we did not observe
VDAC1/BclxL interaction in empty vector or BclxL-ER-
expressing BT549ShBclx (Figure 5b and Supplementary
Figure S5A). Also, cell-permeant N-terminal (amino acids
10–26 of VDAC1) and L14-15 (amino acids 208–218 of
VDAC1) peptides, which alter binding of BclxL to VDAC1/3,35
completely inhibited CD95-mediated mitochondrial Ca2+
influx (Figure 5c and Supplementary Figure S5B) and
cell migration (Figure 5d and Supplementary Figure S5C) in
MEFs and TNBC cells. Ca2+ can accumulate in the
mitochondrial matrix through activation of MCU residing in
the inner mitochondrial membrane.37,38 Pre-treatment of
BT549ShBclx reconstituted with BclxL-WT or BclxL-MT with
a selective MCU inhibitor, Ru360,38 not only prevented
CD95-mediated mitochondrial Ca2+ influx (Figure 6a) but
also abrogated cell migration (Figure 6b). Inhibition of MCU
activity also inhibited CD95-mediated mitochondrial Ca2+
loading (Supplementary Figure S6A) and cell migration
(Supplementary Figure S6B) in MEF cells. Because it was
recently reported that short-term Ca2+ loading in mitochon-
dria can drive ATP production,39 we asked whether mito-
chondrial Ca2+ accumulation observed in cancer cells
stimulated with cl-CD95L was instrumental in producing the
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Figure 4 Localization of BclxL in the outer mitochondrial membrane is pivotal to induce CD95-mediated cell migration. (a) BT549 cells infected with a shRNA targeting the
Bclx 3′ untranslated region (ShBclx#54) were reconstituted with BclxL-WT, BclxL-ER, or BclxL-MT devoid of the 3′ untranslated region. Cells were lysed and the expression levels
of the indicated proteins were evaluated by immunoblotting. (b) Cells in (a) were loaded with the Ca2+ probe Fluo2 and stimulated with cl-CD95L (100 ng/ml). [Ca2+]i was
monitored via the ratio F/F0 (relative Ca
2+
[CYT]). Data represent the mean± s.e. of the mean of F/F0 in GFP-positive cells (n450 cells, at least three independent experiments).
(c) Migration of cells depicted in (a) was analyzed by the Boyden chamber assay for 24 h in the presence (100 ng/ml) or absence of cl-CD95L. Migrating cells were stained with
Giemsa and lysed. Absorbance was measured at a wavelength of 560 nm. Values represent the mean± standard deviation of three independently performed experiments
(*Po0.05; two-way Mann-Whitney). (d) Bclx-deficient BT549 cells (BT549ShBclx) reconstituted with BclxL-MT were loaded with the Ca2+ probe Fluo2 and pre-incubated for 1 h in
the presence or absence of a non-toxic dose of ABT-199 (1 μM). Cells were then stimulated with 100 ng/ml cl-CD95L (black arrow), and [Ca2+]i was monitored via the ratio F/F0
(relative Ca2+[CYT]). Data represent the mean± standard error of the mean of F/F0 in GFP-positive cells (n450 cells, at least three independent experiments). (e) BT549
ShBclx-
BclxL-MTwere pre-incubated for 1 h with or without ABT-199 (1 μM) and then treated or untreated with cl-CD95L (100 ng/ml) for 24 h. Cell migration was analyzed using the
Boyden chamber assay. Migrating cells were fixed with methanol, stained with Giemsa, and lysed. Absorbance was measured at a wavelength of 560 nm. Values represent the
mean± standard deviation of three independently performed experiments (**Po0.01; two-way Mann-Whitney)
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Figure 5 Calcium entry into mitochondria is driven by a BclxL/VDAC1 interaction, which promotes cell motility. (a) Bclx-KO MEFs reconstituted with BclxL-MT (MEFBclxL-MT)
or BclxL-ER (MEFBclxL-ER) were stimulated with cl-CD95L (100 ng/ml) for the indicated amount of time. Cells were lysed and BclxL was immunoprecipitated.
The immunoprecipitated complex was resolved by SDS-PAGE and immunoblotted with anti-BclxL and anti-VDAC1 antibodies. MEFBclxL− /− were used as a negative control.
(b) The experiment in (a) was performed with BT549ShBclx reconstituted with BclxL-MT or BclxL-ER. (c) BclxL-deficient MEFs reconstituted with BclxL-WT were loaded with the
mitochondrial Ca2+ probe (Rhod2) and cell-permeable Mitotracker Green. Representative graphs (10 cells) depicting the relative mitochondrial calcium concentration in control
cells (left panel) and L14-15- (middle panel) and N-Ter (right panel)-treated cells (1 μM, 1 h) are shown. (d) BclxL-KO MEFs reconstituted with BclxL-WT (MEFBclxL-WT) or
BclxL-MT (MEFBclxL-MT) were pre-incubated with the indicated cell-penetrating peptides (1 μM) for 1 h and then stimulated with or without cl-CD95L (100 ng/ml). Cell migration
was evaluated by the Boyden chamber assay. Migrating cells were fixed and stained with Giemsa. For each experiment, five images of random fields were acquired. To quantify
cell migration, migrating cells were lysed and absorbance was measured at a wavelength of 560 nm. Values represent the mean± standard deviation of three independently
performed experiments (**Po0.01, *Po0.05; two-way Mann-Whitney)
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energy required for cell migration. BclxL-KO MEFs stimulated
with cl-CD95L failed to increase ATP production
(Supplementary Figure S7A), while reconstitution of these
cells with BclxL-WT or BclxL-MT restored the increased ATP
production (Supplementary Figure S7A). By contrast,
redistribution of BclxL to the ER membrane failed to
generate ATP in the presence of cl-CD95L (Supplementary
Figure S7A). Of interest, inhibition of the interaction between
BclxL and VDAC1 using the L14-15 peptide (Supplementary
Figure S7B) or of MCU activity using Ru360 (Supplementary
Figure 6 MCU orchestrates Ca2+ entry into mitochondria of cells exposed to cl-CD95L. (a) BT549ShBclx cells reconstituted with BclxL-WT (BT549-BclxL-WT, upper panels) or
BclxL-MT (BT549-BclxL-MT, lower panels) were loaded with a mitochondrial Ca2+ probe (Rhod2, red) and cell-permeable Mitotracker (green) to label mitochondria. Cells were
pre-incubated for 1 h with a non-toxic amount of Ru360 (10 μM) and stimulated with cl-CD95L (100 ng/ml). Graphs depict the relative mitochondrial calcium concentrations in the
indicated cells pre-treated with vehicle (left panel) or Ru360 (10 μM, right panel). (b) BT549ShBclx reconstituted with BclxL-WT and BclxL-MT cells were pre-incubated with Ru360
(10 μM) for 1 h and then stimulated with or without cl-CD95L (100 ng/ml). Cell migration was evaluated by the Boyden chamber assay. Migrating cells were fixed and stained with
Giemsa. For each experiment, five images of random fields were acquired. To quantify cell migration, migrating cells were lysed and absorbance was measured at a wavelength of
560 nm. Values represent the mean± standard deviation of three independently performed experiments (**Po0.01, *Po0.05; two-way Mann-Whitney)
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Figure S7B) abrogated CD95-induced ATP production. This
shows that the BclxL/VDAC1/MCU complex in cells stimu-
lated with cl-CD95L orchestrates ATP production necessary
for cell migration (Figure 7).
Discussion
This study revealed that the anti-apoptotic members Bcl-2 and
BclxL contribute to the migration of TNBC cells exposed to
cl-CD95L, recapitulating TNBC women with the poorest
prognosis.15 We provide novel insights into an original
molecular mechanism by which BclxL and Bcl-2 cooperate
to promote cell migration (Figure 7). Of note, the activity of
pyruvate dehydrogenase, an enzyme linking glycolysis to the
tricarboxylic acid cycle and ATP production, is positively
regulated by Ca2+ in the mitochondrial matrix.40 In this regard,
whereas pyruvate dehydrogenase phosphorylation by pyru-
vate kinase suppresses its activity, its dephosphorylation by
Ca2+-dependent pyruvate phosphatase enhances its
activity.41 Therefore, we envision that CD95-mediated mito-
chondrial Ca2+ loading enhances pyruvate phosphatase
activity, which in turn activates pyruvate dehydrogenase to
promote mitochondrial respiration and ATP production.
Our findings demonstrate that although BclxL expression at
the ER membrane restores a cytosolic Ca2+ signal, it cannot
evoke Ca2+ passage from ER stores to the mitochondrial
matrix. By contrast, its mitochondrion-restricted isoform
promotes this mitochondrial Ca2+ uptake but fails to restore
the ‘wild-type’ cytosolic Ca2+ signal, indicating that mitochon-
drion- and ER-localized BclxL contribute to different Ca2+ cues
and that both distributions are mandatory to evoke a complete
Ca2+ response in malignant cells exposed to cl-CD95L.
Interestingly, the Bcl-2 selective BH3 mimetic ABT-199
abrogated both cytosolic and mitochondrial Ca2+ signals.
Because the CD95-mediated Ca2+ response is initiated by
IP3R-dependent depletion of ER Ca2+ stores followed by
extracellular Ca2+ influx via activation of the plasma mem-
brane channel ORAI1,12,15,42 these findings suggest that Bcl-2
can control IP3R activity in a BH3-dependent manner (see
Figure7). However, this contradicts various studies showing
that Bcl-2 and BclxL mainly modulate the release of Ca2+ from
ER through an interaction of their BH4 domain with IP3R.43
Nonetheless, it is noteworthy that Bcl-2 and BclxL participate
in hubs that modulate various cellular outcomes such as cell
survival, proliferation, and metabolism.44 Most, if not all,
studies evaluating Bcl-2- and BclxL-dependent regulation of
IP3R focused on its effect in the implementation of the
apoptotic signaling pathway.43 Therefore, we postulate that
similar to death receptors that can implement opposite
signaling pathways according to the cellular context (normal
versus transformed cells13,14,45,46) or the ligand with which
they interact (soluble versus transmembrane11,12,15), IP3Rs
are involved in different molecular complexes, which might be
regulated in a different manner by Bcl-2 family members.
Our data also provide insight into how loss of BclxL in the ER
membrane impairs the CD95-mediated cytosolic Ca2+
response, showing that even if Bcl-2 participates in Ca2+
release fromER stores, its presence is not sufficient to evoke a
‘wild-type’ cytosolic Ca2+ response. To explain why there is no
redundancy among the Bcl-2 family in the cl-CD95L-mediated
Ca2+ signal, we envision that Bcl-2 and BclxL coordinate the
efficient release of Ca2+ from the ER by acting on different
partners in a large IP3R(s) complex or by modulating the
activity of different IP3R isoforms necessary for transmitting a
complete Ca2+ response. Our study also reveals the complex
interplay between these two Bcl-2 members in the regulation
of Ca2+ flux from the ER to the mitochondrial matrix.
Of note, high-calcium microdomains are observed in the
lamella of migrating cells and are involved in guiding cells.47
Accordingly, Ca2+ buffering by mitochondria and its control by
Bcl-2 and BclxL may be essential to steer cells across a
cl-CD95L gradient in TNBC tissues.
IP3R can be phosphorylated by Akt, resulting in
reduced Ca2+ efflux from the ER and less apoptosis.48 Of
note, whereas the BH3 mimetic ABT-737 did not affect
CD95-mediated Akt phosphorylation (Figure 1b), silencing of
BclxL or Bcl-2 enhanced Akt activation (Supplementary
Figure S1F), indicating that Bcl-2/BclxL-driven PI3K/Akt
regulation occurs through a BH3-independent mechanism,
which remains to be identified. However, our data led us to
hypothesize that by reducing the intensity of PI3K/Akt
signaling induced by cl-CD95L in TNBC cells, BclxL and
Bcl-2 may enhance IP3R activity and thereby promote Ca2+
flux from the ER to mitochondria to produce more ATP, fueling
cell migration.
A phase II clinical trial demonstrated that a decoy CD95
receptor, APG101, can impede the CD95/CD95L interaction in
humans suffering from glioblastoma and allow partial
response in these patients.49 Although APG101 may repre-
sent a short-term therapeutic approach for TNBC patients, its
inability to discriminate between the anti-tumor/infectious
(i.e., apoptotic signaling) and the pro-inflammatory actions of
CD95 may engender, if used in a chronic manner, unexpected
adverse events such as infection and tumor relapse.
Overall, this study highlights that the classical ‘apoptotic
machinery’ is instrumental in cell migration. Therefore, tumor
cells are not only selected according to their ability to resist
apoptotic signaling pathways but also their capacity to use this
‘apoptotic machinery’ in order to becomemore aggressive and
thus metastatic. Navitoclax, also designated ABT-263, is an
orally bioavailable derivative of ABT-73750 that unfortunately
showed side effects such as thrombocytopenia in phase II
clinical trials.51 Our results indicate that a combination of low
doses of navitoclax with classical chemotherapy applied in
TNBC women is an attractive therapeutic option not only to
reduce the risk of metastatic dissemination in patients with a
high serum concentration of CD95L but also to decrease the
side effects observed when this drug is used at cytotoxic
doses.52
Materials and Methods
Cell lines and shRNAmir lentiviral transduction. BclxL-KO MEF cells
were described earlier53 and BAD-KO MEF cells were from Dr P Juin (Nantes,
France). BAX/BAK double KO MEF cells were kindly provided by Dr D Arnoult
(Villejuif, France). TNBC cell lines, MDA-MB-231 and BT549, and MEF cell lines,
Bcl-2 KO and BID KO, were obtained from ATCC (LGC Standards, Molsheim,
France). All cells were cultured in DMEM supplemented with 8% v/v heat-inactivated
FCS and 2 mM L-glutamine at 37 °C in a 5% CO2 incubator. Silencing experiments
were performed using lentiviral vector encoding shRNA targeting Bclx (RHS4430-
101108659; RHS4430-99157776; RHS4430-99890586; RHS4430-99883769; RHS4430-
99881577), Bcl-2 (RHS4430-98901868; RHS4430-98851633; RHS4430-101159334)
BclxL orchestrates CD95-mediated cell migration
A Fouqué et al
1713
Cell Death and Differentiation
or a scrambled shRNAmir (negative control) (OpenBiosystems, Waltham, MA, USA).
Then, cells stably expressing shRNA were selected for 7 days using 0.5 μg/ml of
puromycin. To reconstitute Bclx-silenced BT549 cells with our BclxL constructs,
shRNA-BclxL-expressing cells were transfected by electroporation with pcDNA3 vector
encoding BclxL-WT, BclxL-Acta (MT) or BclxL-CytB5 (ER) or empty vector. Twenty-four
hours after transfection, cells were placed in a medium supplemented with 0.6 mg/ml of
neomycin. Neomycin-resistant colonies were isolated using cloning cylinders (Bellco
Glass, Vineland, NJ, USA).
Antibodies, plasmids, and reagents. ABT-737 and ABT-199 were
obtained from Selleckchem (Houston, TX, USA). Anti-β-actin was purchased from
Sigma (L’Isle-d’Abeau-Chesnes, France). Anti-BclxL, anti-Bcl-2, anti-Akt, anti-
phosphoS473 Akt, anti-phosphoThr308 Akt, and anti-BAD were from Cell Signaling
Technology (Boston, MA, USA). Anti-BID mAb was from Millipore (Molsheim,
France). Anti-BclxL (clone E18) and anti-VDAC1 (ab14734) were purchased from
Abcam (Cambridge, UK). Anti-CD95 (C20), anti-VDAC1, and Ru360 were
purchased from Santa Cruz (Santa Cruz, CA, USA). Duolink kits (DUO92102)
were purchased from Sigma-Aldrich (St. Louis, MO, USA).
N-terminal peptide (LGKSARDVFTKGYGFG) and L14-15 peptide (LAW-
TAGNSNTR) (VDAC1 sequences) were synthesized by SynPeptide (Shanghai,
China). These peptides were coupled with the cell-permeant sequence of
antennapedia homeodomain (RQIKIWFQNRRMKWKK) to their C-terminal domain.
IgCD95L and metalloprotease-cleaved CD95L were generated in the laboratory.12
FuraPE3 and Fluo2-AM were from Euromedex (Souffelweyersheim, France);
mitotracker green and Rhod2-AM were from Life Technologies SAS (Saint Aubin,
France); and BAPTA-AM from Sigma.
GFP sequence lacking stop codon was amplified by PCR from pEGFPN1
sequence using primer pair: sense CGGGATCCATGGTGAGCAAGGGCGAGGAG
CTG and antisense CCGCTCGAGCTTGTACAGCTCGTCCATGCCG. The ampli-
cons was digested by Xho1 and BamH1 and inserted into Xho1 and BamH1-cleaved
pcDNA3.1(+). Next, pcDNA3.1(+)-GFP was linearized using XhoI/XbaI and
sequences corresponding to amino acid residues 107–142 of human CytB5
(ITTIDSSSSWWTNWVIPAISAVAVALMYRLYMAED) or residues 613–639 of Acta
(‘Actin Assembly inducing protein’) (LILAMLAIGVFSLGAFIKIIQLRKNN) synthesized
by Sigma-Aldrich were inserted in frame with the GFP sequence.
BclxL (amino acid residues 1–209) lacking transmembrane region weas amplified
by PCR using pCMV-BclxL (Origene, Rockville, MD, USA) as a template with the
following primer pair: (BCLx sense) 5′ CCCAAGCTTATGTCTCAGAGCAACCG
GGAGC 3′, (BCLx antisense) 5′ CCCTCGAGGCGTTCCTGGCCCTTTCGGC 3′.
Amplicon was digested by HindIII/XhoI and inserted into HindIII/XhoI-digested
pCDNA3.1(+)-GFP-Acta or pCDNA3.1(+)-GFP-CytB5 vectors to generate pcDNA3.1
(+)-BclxL-Acta (BclxL-MT), pcDNA3.1(+)-BclxL-CytB5 (BclxL-ER) constructs. All
constructs were validated by sequencing (GATC Biotech, Mulhouse, France).
Figure 7 CD95-mediated cell migration occurs through a Bcl-2/BclxL/VDAC1/MCU-driven mitochondrial calcium loading. Death-inducing signaling complex (DISC) and
motility-inducing signaling complex (MISC) are formed through protein–protein interaction. For the CD95-mediated apoptotic signaling pathway, type II cells (e.g., hepatocytes)
rely on the release of apoptotic factors (i.e., cytochrome c, smac/Diablo, Omi/Hrt2A) by the mitochondria to implement the apoptotic cue while Type I (e.g., T lymphocytes) does
not. The CD95-mediated calcium response is initiated by PLCγ1 activation leading to release of the ER-stored Ca2+ in the cytosol (1), followed by a store-operated calcium entry
(SOCE) through activation of the Ca2+ channel Orai1 (2). This study shows the pivotal role played by the calcium transfer from ER to mitochondria (3) in TNBC cell migration
induced by cl-CD95L
BclxL orchestrates CD95-mediated cell migration
A Fouqué et al
1714
Cell Death and Differentiation
Immunoblot analysis. Cells were lysed for 30 min at 4 °C in lysis buffer
(25 mM HEPES (pH 7.4), 1% Triton X-100, 150 mM NaCl, and 2 mM EGTA
supplemented with a mix of protease and phosphatase inhibitors (Sigma)). Protein
concentration was determined by the bicinchoninic acid method (Pierce, Rockford,
IL, USA). Proteins were resolved by SDS-PAGE and transferred to a nitrocellulose
membrane. The membrane was blocked for 30 min with TBST (50 mM Tris,
160 mM NaCl, 0.05% Tween 20, pH 7.8) containing 5% w/v dried skimmed milk or
5% BSA and then incubated overnight with primary antibody at 4 °C. The
membrane was washed (TBST) and secondary HRP-labeled antibody (South-
ernBiotech, Birmingham, AL, USA) was added for 1 h. The proteins were visualized
with the enhanced chemiluminescence substrate kit (Pierce).
Immunoprecipitation. MEFBclxL-MT and MEFBclxL-ER cells or BT-549shBclx-
BclxL-MT and BT-549shBclx-BclxL-ER (107 cells) were stimulated with cl-CD95L for
the indicated times and then lysed. Lysate was incubated for 1 h at 4 °C with 1 μg
of anti-BclxL mAb (clone E18) and BclxL was immunoprecipitated using proteins
A/G-conjugated magnetic beads (Ademtech, Pessac, France). After extensive
washing, the immune complex was resolved by SDS-PAGE and immunoblotting
were performed.
Measure of cell death. Cell death was assessed using viability MTTassay as
described previously.54
Calcium monitoring. Single-cell cytosolic calcium imaging was performed
ratiometrically, using FuraPE3-AM calcium dye, as described previously.16
Coverslips were mounted in a recording chamber positioned on the stage of an
inverted epifluorescence microscope (IX70, Olympus, Tokyo, Japan) equipped with
an × 40 UApo/340-1.15 W objective. Cells were loaded with 5 μM FuraPE3-AM at
room temperature in Hank’s Balanced Salt Solution (HBSS) for 30 min. FuraPE3-
AM exhibits limited compartmentalization in intracellular stores and is leakage-
resistant.55 The cells were rinsed with HBSS and incubated in the absence of the
Ca2+ probe for 15 min to complete de-esterification of the dye. Fluorescence
micrograph images were captured at 510 nm and at 12-bit resolution by a fast-scan
camera (CoolSNAP fx Monochrome, Photometrics, Tucson, AZ, US). FuraPE3-AM
was excited at 340 and 380 nm alternately and the ratios of the resulting images
were produced at constant 10-s intervals. Regions of interest were drawn on certain
recorded cells to restrict data collection to specific regions. Imaging was controlled
by Universal Imaging software, including Metafluor and Metamorph. Data were
processed using OriginPro 7.5 software (Origin Lab, Northampton, MA, USA).
For experiments on GFP-expressing cell lines, Fluo2-AM was used, because GFP
fluorescence disturbs Ca2+ measurement with FuraPE3. ShRNA-transduced cells
(GFPexpressing cells) were located by their emission of fluorescence at 530 nm for a
light excitation at 485 nm. Ca2+ changes were evaluated by exciting Fluo2-AM-loaded
cells at 535nm. The values of the emitted fluorescence (605 nm) for each cell
(F) were normalized to the starting fluorescence (F0) and reported as F/F0 (relative
Ca2+[CYT]). Only GFP-positive cells were considered. Cells were loaded with Fluo2-
AM (1 μM) for 30 min and then incubated for 15 min in HBSS to complete
de-esterification of the dye.
Single-cell mitochondrial calcium imaging was performed on Rhod2, and
mitotracker-loaded cells. Cells were loaded with 3 μM Rhod2-AM and mitotracker
green at room temperature in HBSS for 120 min. Mitotracker green and Rhod2 were
alternately excited using the 488- and 568-nm lines, respectively, of a krypton-argon
laser. Emitted fluorescence was acquired using a Zeiss LSM 510 meta confocal
microscope (Zeiss, Göttingen, Germany) equipped with an ApoPLAN × 63 objective.
The emitted fluorescence was filtered using a dual bandpass filter set and collected
and analyzed using Zeiss software. In some experiments, cells were placed in a
Ca2+-free medium (HBSS in which CaCl2 was omitted and 100 μM EGTA). This
medium was added to the cells just before recording to avoid leak of the intracellular
calcium stores. Data from ~ 30 cells were acquired per field. One field was acquired
from each coverslip and the data pooled from six independent coverslips on three
different days. Fluorescence intensity changes were normalized to the initial
fluorescence value F0 and expressed as F/F0. Data were summarized as mean
+/− S.E.M.
Proximity ligation assay. BclxL-deficient BT549 cells reconstituted with
BclxL-WT, BclxL-MT, and BclxL-ER were let adhere to coverslip for 24 h. Then, cells
were stimulated with or without cl-CD95L (100 ng/ml) for 15 min. After extensive
washes with PBS, cells were fixed and permeabilized with ethanol (70%) for 20 min
at − 20 °C. Cells were blocked with PBS-5% FCS for 20 min at RT, then incubated
for 20 min at 4 °C with a mix of primary antibody consisting of anti-VDAC1
(ab14734) and anti-BclxL (clone E18) diluted to 1:500 in PBS-5% FCS. Following
steps were realized according to the manufacturer recommendations.
Motility assays. After membrane hydration of Boyden chambers (Millipore)
containing 8 μm pore membranes, 105 cells were added to the top chamber. The
bottom chamber was filled with low serum (1%)-containing medium in the presence
or absence of cl-CD95L (100 ng/ml). After 24 h, cells were fixed with methanol and
stained with Giemsa. Stained cells were then removed from the top side of the
membrane using a cotton-tipped swab and five representative pictures were taken
of cells that have migrated to the membrane reverse side. For each experiment,
invading cells were lysed and absorbance at 560 nm was measured.
Intracellular ATP measurement. Mitochondrial ATP levels were measured
by transfecting MEF cells with the mitochondrion-targeted FRET-based probe
(Mito-ATEAM), as previously described.56 Briefly, cells seeded on coverslips were
washed in a modified Ringer's medium (in mM: 140 NaCl, 5 KCl, 1 MgCl2, 2 CaCl2,
10 HEPES, and 10 glucose at pH 7.3) and images were collected using 440 nm
excitation and alternate 475/535 nm emission on an Axiovert S100 TV microscope
through a × 40, 1.3 NA oil-immersion objective (Carl Zeiss, Oberkochen, Germany)
equipped with a 16-bit CCD camera, Xenon lamp and filter-based wavelength
switcher (Visitron Systems, Puchheim, Germany). Relative changes in mitochondrial
ATP are reported as background-subtracted FRET.
Statistical analysis. Two-tailed Mann–Whitney non-parametrical tests were
used for comparison of means.
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